Original Research Articles

Overacre-Delgoffe AE, Bumgarner HA, Cillo AR, Burr AHP, Tometich JT, Tabib T, Lafyatis R, Vignali DAA, Hand TW. “Microbiota-specific T cells drive tertiary lymphoid structures and anti-tumor immunity in colorectal cancer.” Immunity. 2021. Dec 14. doi: 10.1016/j.immuni.2021.11.003.

Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, Shuai Y, Normolle DP, Kirkwood JM, Ferris RL, Delgoffe GM, Bruno TB, Workman CJ, Vignali DAA. “Interferon-γ drives Treg fragility to promote anti-tumor immunity.” Cell. 2017 June 1;169(6):1130-1141. doi: 10.1016/j.cell.2017.05.005.

Reviews

Hand, TW and Overacre-Delgoffe, AE. “The complex immunological role of Helicobacter in modulating cancer.” Trends in Immunology. 2022 Oct. doi: 10.1016/j.it.2022.08.002.

Overacre-Delgoffe AE, Hand, TW. “Regulation of Tissue-Resident T cells by the Microbiota.” in review, Mucosal Immunology. 2021. Feb 22. doi: 10.1038/s41385-022-00491-1.

Marron TU, Ryan AE, Reddy SM, Kaczanowska S, Younis RH, Thakkar D, Zhang J, Bartkowiak T, Howard R, Anderson KG, Olson D, Naqash AR, Patel RB, Sachdev E, Rodríguez-Ruiz ME, Sheffer M, Church SE, Fuhrman C, Overacre-Delgoffe AE, Nguyen R, Florou V, Thaxton J, Aggen DH, and Guerriero JL. Considerations for treatment duration in responders to immune checkpoint inhibitors. JITC. 2021 Mar;9(3):e001901. doi: 10.1136/jitc-2020-001901.

Overacre-Delgoffe AE, Vignali, DA. “Treg fragility: a prerequisite for effective anti-tumor immunity?” Cancer Immunology Research. 2018 Aug;6(8):882-887. doi: 10.1158/2326-6066.

Overacre AE, Vignali, DA. “Treg stability: to be or not to be?” Curr Opin Immunol. 2016 April;39:39-43. doi: 10/1016/j.coi.2015.12.009.

Overacre AE, Kurtulus S, Sznol M, Pardoll D, Anderson A, Vignali DA. “Combination immunotherapy: Where do we go from here?” JITC. 2015 Aug 3:38.

Collaborative Research

Bhattacharjee A, Burr AB, Overacre-Delgoffe AE, Tometich JT, Yang D, Huckestein BR, Linehan JL, Spencer SP, Hall JA, Harrison OJ, Morais da Fonseca D, Norton EB, Belkaid Y, Hand TW. “Environmental enteric dysfunction induces regulatory T cells that inhibit local CD4+ T cell responses and impair oral vaccine efficacy.” Immunity. 2021. Aug 10. doi: 10.1016/j.immuni.2021.07.005.

Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta R, Grebinowski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM. “Metabolic support of tumor-infiltrating regulatory T cells by lactic acid.” Nature. 2021 Feb 15. doi: 10.1038/s41586-020-03045-2.

Chuckran CA, Cillo AR, Moskovitz J, Overacre-Delgoffe AE, Somasundaram AS, Magnon GC, Abecassis I, Zureikat AH, Luketich J, Pennathur A, Sembrat J, Rojas M, Merrick DT, Taylor SE, Orr B, Modugno F, Bukanovich R, Schoen RE, Kim S, Duvvuri U, Zeh H, Edwards R, Kirkwood JM, Coffman L, Ferris RL, Bruno TC, Vignali DAA. “Neuropilin-1 enforces human regulatory T cell stability and function in solid tumors.” Science Translational Medicine. In press. 2021.

Delgoffe GM*, Woo SR*, Turnis ME, Guy CS, Gravano DM, Overacre AE, Bettini ML, Finkelstein DF, Vogel P, Workman CJ and Vignali DA. “Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis.” Nature. 2013 Sep 12;501(7466):252-6. doi:10.1038/nature12428.

Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, Zhang H, Huppa JB, Tsai YH, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DA. “Distinct TCR signaling pathways drive proliferation and cytokine production in T cells.” Nat Immunol. 2013 Mar;14(3):262-70. doi: 10.1038/ni.2538.